Alzheimer’s disease starts with invisible changes in the brain that begin 15 to 20 years before any symptoms appear. The first detectable sign is a slow buildup of a sticky protein fragment called amyloid-beta, which clumps together between nerve cells in a region deep in the brain involved in forming new memories. By the time someone notices they’re forgetting conversations or misplacing things more than usual, the disease has already been progressing silently for well over a decade.
What Happens Inside the Brain First
The process begins with amyloid-beta, a small protein fragment that is produced normally in the brain throughout life. In Alzheimer’s, these fragments aren’t cleared away efficiently. Instead, they stick together, first forming small clusters called oligomers and eventually building up into the dense plaques visible on brain scans. These early clusters are thought to be the more damaging form, interfering with signaling between nerve cells before full plaques even develop.
A second protein, called tau, goes wrong shortly after. Tau normally acts like scaffolding inside neurons, stabilizing the internal transport system that moves nutrients and chemical signals from one end of the cell to the other. In Alzheimer’s, tau becomes chemically altered through a process called hyperphosphorylation. This causes it to detach from the cell’s internal structure, and the freed tau molecules clump together into twisted fibers called neurofibrillary tangles. Once the scaffolding collapses, the neuron can no longer transport what it needs to survive. Its branches wither, and eventually the cell dies.
These two processes, amyloid buildup outside cells and tau tangles inside them, are the biological signature of Alzheimer’s. They don’t happen everywhere at once. They follow a predictable path through the brain.
Where It Starts and How It Spreads
The earliest tau tangles appear in a structure called the entorhinal cortex, a small area tucked beneath the temples that serves as the brain’s gateway for forming new memories. Tangles begin specifically in a thin layer of cells near the border of the entorhinal cortex, a region that connects directly to the hippocampus, the brain’s primary memory center. At this point, a person has no noticeable symptoms. Researchers classify this as Braak stages I and II, the earliest anatomical phase of the disease.
From there, the tangles spread along neural connections into the hippocampus itself. This is the stage where mild cognitive impairment, or MCI, typically begins to show. A person might struggle to recall recent events or lose track of a conversation more often than their peers. As the disease advances further (Braak stages V and VI), tangles reach the outer cortex, the regions responsible for language, reasoning, spatial awareness, and eventually basic body functions. The toxic proteins appear to travel between neurons through their synaptic connections, essentially hijacking the brain’s own communication network to spread.
The Brain’s Immune System Turns Harmful
The brain has its own immune cells, called microglia, that normally clean up debris and prune unnecessary connections between neurons. In Alzheimer’s, these cells shift from protective to destructive. Microglia respond to amyloid buildup by triggering chronic inflammation, and this inflammatory response is now understood to be an active driver of the disease rather than just a side effect.
One of the most damaging things microglia do in Alzheimer’s is strip away synapses, the junctions where neurons communicate. They do this through a system borrowed from the body’s broader immune defense called the complement cascade. In healthy brains, this system helps tag weak or unused synapses for removal during development. In Alzheimer’s, it becomes overactivated. Studies in animal models have shown that complement-driven synapse destruction begins before amyloid plaques are even visible, correlating instead with levels of soluble amyloid fragments. When researchers blocked this complement system, synapse loss was significantly reduced. Microglia also contribute to the spread of tau tangles throughout the brain and promote the chemical changes that make tau toxic in the first place.
Blood Flow Problems May Come Even Earlier
There is growing evidence that damage to the brain’s blood supply plays a role in initiating the disease, not just worsening it. The blood-brain barrier, a tightly sealed lining of blood vessels that controls what enters brain tissue, shows signs of breaking down early in Alzheimer’s, before cognitive decline or significant neurodegeneration is detectable.
One prominent theory, known as the two-hit vascular hypothesis, proposes that damage to the brain’s blood vessels is the first insult. This vascular damage alone can injure neurons, but it also impairs the brain’s ability to clear amyloid-beta, causing it to accumulate. Early in the disease, the transporters that move glucose across the blood-brain barrier are downregulated, meaning neurons start to receive less fuel. Reduced blood flow compounds the problem. People who carry the APOE4 gene variant (more on this below) show blood-brain barrier breakdown and reduced cerebral blood flow even independent of amyloid buildup, suggesting that vascular damage may be one of the earliest events in their path to the disease.
The Silent Timeline
For someone who develops preclinical Alzheimer’s around age 70, the total disease course is roughly 20 years. The first 10 of those years are entirely silent, with amyloid and tau accumulating but no symptoms a person or their doctor would notice. This is followed by about 4 years of a prodromal stage, where subtle cognitive changes emerge but don’t yet meet the threshold for a dementia diagnosis. Mild dementia lasts approximately 3 years, followed by moderate dementia for another 3 years. These are averages, and individual variation is significant.
The 2024 diagnostic criteria from the National Institute on Aging and the Alzheimer’s Association now define the disease biologically rather than by symptoms. Under this framework, Alzheimer’s is considered present as soon as biomarkers, detectable through brain imaging, spinal fluid tests, or newer blood-based tests, confirm the presence of amyloid and tau pathology. A person can have Alzheimer’s disease by this definition while still feeling completely normal.
Genetics and the APOE4 Gene
The single strongest genetic risk factor for common, late-onset Alzheimer’s is the APOE4 variant of the apolipoprotein E gene. Everyone inherits two copies of the APOE gene, one from each parent, and the versions you carry significantly affect your risk. People with two copies of APOE4 have roughly a 60% chance of developing Alzheimer’s dementia by age 85. They tend to experience symptoms around age 65 on average, with a formal dementia diagnosis around 74, all of which is 7 to 10 years earlier than people without any APOE4 copies. A 2024 NIH-supported study went so far as to characterize having two APOE4 copies as a distinct genetic form of Alzheimer’s rather than simply a risk factor.
Carrying one copy of APOE4 raises risk to a lesser degree. Many people with one or even two copies never develop dementia, and many people with no copies do. APOE4 is a risk modifier, not a guarantee.
Modifiable Factors Linked to Earlier Onset
While genetics loads the gun, lifestyle and health conditions influence when and whether the trigger gets pulled. CDC data from over 30 states found that adults with early signs of cognitive decline were nearly three times as likely to report four or more modifiable risk factors compared to those without cognitive concerns. The factors most strongly associated with early cognitive symptoms were depression (28.5% of people with depression reported subjective cognitive decline), hearing loss (24.7%), current smoking (18.4%), diabetes (17.4%), and physical inactivity (14.5%).
High blood pressure, obesity, and excessive alcohol use round out the list. These factors don’t cause Alzheimer’s in the way a virus causes an infection, but they appear to accelerate or unmask the underlying pathology. Vascular risk factors like hypertension and diabetes are particularly notable because they directly affect blood flow to the brain, potentially worsening the blood-brain barrier damage described earlier. Depression may reflect early neuroinflammatory changes or may independently accelerate neuronal loss. Hearing loss is thought to reduce cognitive stimulation and increase social isolation, both of which weaken the brain’s resilience against accumulating damage.
Normal Aging Versus Early Alzheimer’s
Occasional forgetfulness is a normal part of getting older. Forgetting where you put your keys, blanking on a name and remembering it later, or needing to reread a paragraph are all typical. What distinguishes mild cognitive impairment, the earliest symptomatic stage of Alzheimer’s, is memory loss that is measurably worse than expected for your age and education level while the rest of your thinking abilities and daily functioning remain intact. In clinical terms, this is defined as scoring about 1.5 standard deviations below the average for age-matched peers on memory tests, though that cutoff is somewhat arbitrary.
The practical difference: normal aging means you forget details but can usually retrieve them with a cue or reminder. Early Alzheimer’s means the information was never solidly stored in the first place, so no amount of prompting brings it back. Repeatedly asking the same question in a single conversation, getting lost in a familiar place, or struggling to follow a recipe you’ve made dozens of times are signs that something beyond normal aging may be happening.